Compare Consolidated Edison, Inc. (ED) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs TG Therapeutics Inc — how do they compare? Consolidated Edison, Inc. trades at $106.11 (market cap $39.20B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Consolidated Edison, Inc. is far larger — about 4.8× TG Therapeutics Inc's market cap, and Consolidated Edison, Inc. pays a 3.31% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and TG Therapeutics Inc for 16 Days on average.
| ED | TGTX | |
|---|---|---|
Market Cap | $39.20B | $8.16B |
Volume | 2,142,900 | 1,735,121 |
Sector | Utilities | Health |
52-Week High | $115.46 | $59.06 |
52-Week Low | $95.37 | $26.94 |
Typical Hold Time | 75 Days | 16 Days |
Enterprise Value | $66.05B | $8.37B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $106.10, up 1.39% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The stock's valuation appears reasonable with a P/E of 17.43 and P/S of 2.18, while profitability metrics like a 12.53% net income margin and 8.96% ROE reflect steady utility performance. Recent earnings showed beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains strong cash flow from operations of $4.80 billion in 2025 and continues its dividend aristocrat status with a recent $0.89 dividend declaration.
ED offers stable income appeal with a solid dividend history, supported by regulated utility operations and a $24.8 billion economic impact in New York. However, high debt levels ($24.65 billion long-term) and modest growth prospects pose risks. Analyst sentiment is cautious with 62.96% hold ratings, though the consensus price target of $106.33 aligns with the current price, suggesting limited near-term upside amid economic sensitivity.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
